The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma

Seminars in Oncology

Volumn 38, Issue SUPPL. 4, 2011, Pages

  Cloughesy, Timothy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CILENGITIDE; CLOBAZAM; CLONAZEPAM; CORTICOSTEROID; COTRIMOXAZOLE; DALTEPARIN; DENDRITIC CELL VACCINE; GABAPENTIN; HYDROXYUREA; IMMUNOMODULATING AGENT; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; LAMOTRIGINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PACLITAXEL; PLACEBO; RINDOPEPIMUT; TALAMPANEL; TEMOZOLOMIDE; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VANDETANIB; WARFARIN; ZONISAMIDE;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTICOAGULANT THERAPY; ANTICONVULSANT THERAPY; BONE MARROW TOXICITY; BRACHYTHERAPY; BRAIN EDEMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL REGENERATION; CHEMORADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CPG ISLAND; DEMOGRAPHY; DNA METHYLATION; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLIOBLASTOMA; GLIOMA CELL; HUMAN; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION SICKNESS; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STANDARD; STEREOTACTIC RADIOSURGERY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; MEDICAL ONCOLOGY; RESEARCH DESIGN; STANDARD OF CARE;

EID: 80855144781     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.09.007     Document Type: Conference Paper

References (59)

1. Central Brain Tumor Registry of the United States CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007 http://www.cbtrus.org/reports/reports.html 2011 Accessed August 16, 2011
2. The NCCN Clinical Practice Guidelines in Oncology Central Nervous System Cancers (Version 2.2011) National Comprehensive Cancer Network, Inc www.nccn.org Accessed August 16, 2011
3. M.D. Walker, E. Alexander Jr, and W.E. Hunt Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas A cooperative clinical trial J Neurosurg 49 1978 333 343 (Pubitemid 9013313)
4. M.D. Walker, S.B. Green, and D.P. Byar Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery N Engl J Med 303 1980 1323 1329 (Pubitemid 11194457)
5. L.A. Stewart Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet 359 2002 1011 1018 (Pubitemid 34286538)
6. S.A. Leibel, P.H. Gutin, and W.M. Wara Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas Int J Radiat Oncol Biol Phys 17 1989 1129 1139 (Pubitemid 20028628)
7. P.H. Gutin, T.L. Phillips, and W.M. Wara Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources J Neurosurg 60 1984 61 68 (Pubitemid 14181556)
8. B. Wowra, H.P. Schmitt, and V. Sturm Incidence of late radiation necrosis with transient mass effect after interstitial low dose rate radiotherapy for cerebral gliomas Acta Neurochir (Wien) 99 1989 104 108 (Pubitemid 19196377)
9. W.J. Curran Jr, C.B. Scott, and A.S. Weinstein Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02 J Clin Oncol 11 1993 857 862 (Pubitemid 23146079)
10. M. Werner-Wasik, C.B. Scott, and D.F. Nelson Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas Radiation Therapy Oncology Group Study 83-02 Cancer 77 1996 1535 1543
11. L. Souhami, W. Seiferheld, and D. Brachman Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol Int J Radiat Oncol Biol Phys 60 2004 853 860 (Pubitemid 39311766)
12. W.R. Shapiro, S.B. Green, and P.C. Burger Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma Brain Tumor Cooperative Group Trial 8001 J Neurosurg 71 1989 1 9 (Pubitemid 19196544)
13. F.H. Hochberg, and A. Pruitt Assumptions in the radiotherapy of glioblastoma Neurology 30 1980 907 911 (Pubitemid 10059239)
14. K.E. Wallner, J.H. Galicich, and G. Krol Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma Int J Radiat Oncol Biol Phys 16 1989 1405 1409 (Pubitemid 19154322)
15. H.K. Kim, A.F. Thornton, and H.S. Greenberg Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy Am J Clin Oncol 20 1997 358 363 (Pubitemid 27329567)
16. K. Nakagawa, Y. Aoki, and T. Fujimaki High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme Int J Radiat Oncol Biol Phys 40 1998 1141 1149 (Pubitemid 28152930)
17. M.D. Prados, D.A. Larson, and K. Lamborn Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors Int J Radiat Oncol Biol Phys 40 1998 57 63 (Pubitemid 28027567)
18. G. Fountzilas, A. Karavelis, and A. Capizzello Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme A phase II study J Neurooncol 45 1999 159 165 (Pubitemid 30197729)
19. A.M.P. Omuro, K. Beal, and S. Karimi Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM) J Clin Oncol 29 Suppl 2011 Abstract 2028
20. E.C. Quant, T. Batchelor, and A.B. Lassman Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM) J Clin Oncol 29 Suppl 2011 Abstract 2069
21. M. Khasraw, S.A. McCowatt, and Z. Kerestes Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric) J Clin Oncol 29 Suppl 2011 Abstract TPS133
22. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996 (Pubitemid 40349501)
23. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group Lancet Oncol 10 2009 459 466
24. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003 (Pubitemid 40349502)
25. M.R. Gilbert, M. Wang, and K.D. Aldape RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) J Clin Oncol 29 Suppl 2011 Abstract 2006
26. A.A. Brandes, E. Franceschi, and A. Tosoni Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status Cancer 115 2009 3512 3518
27. M. Esteller, J. Garcia-Foncillas, and E. Andion Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 2000 1350 1354
28. S. Spiegl-Kreinecker, C. Pirker, and M. Filipits O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients Neurooncol 12 2010 28 36
29. D.W. Parsons, S. Jones, and X. Zhang An integrated analysis of human glioblastoma multiforme Science 321 2008 1807 1812
30. S. Combs, A. Abdollahi, and S. Rieken Validation of prognostic significance of IDH1 and MGMT in patients with glioblastoma: one step forward, and one step back? American Society for Radiation Oncology 52nd Annual Meeting October 31-November 4, San Diego, CA 2010 Abstract 20
31. H. Noushmehr, D.J. Weisenberger, and K. Diefes Identification of a CpG island methylator phenotype that defines a distinct subgroup of gliomas Cancer Cell 17 2010 510 522
32. R.O. Mirimanoff, T. Gorlia, and W. Mason Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial J Clin Oncol 24 2006 2563 2569 (Pubitemid 46630635)
33. C.B. Scott, C. Scarantino, and R. Urtasun Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06 Int J Radiat Oncol Biol Phys 40 1998 51 55 (Pubitemid 28027566)
34. P.Y. Wen, D.R. Macdonald, and D.A. Reardon Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group J Clin Oncol 28 2010 1963 1972
35. M.C. de Wit, H.G. de Bruin, and W. Eijkenboom Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression Neurology 63 2004 535 537 (Pubitemid 39031388)
36. K. Lutz, A. Radbruch, and B. Wiestler Neuroradiological response criteria for high-grade gliomas Clin Neuroradiol 2011 June 17 [Epub ahead of print]
37. S.A. Grossman, Y. Xiaobu, and S. Piantadosi Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States Clin Cancer Res 16 2010 2443 2449
38. D.A. Reardon, E. Galanis, and J.F. DeGroot Clinical trial end points for high-grade glioma: the evolving landscape Neurooncol 13 2011 353 361
39. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
40. J.J. Vredenburgh, A. Desjardins, and D.A. Reardon Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM) J Clin Oncol 29 Suppl 2011 Abstract 2098
41. S.A. Grossman, X. Ye, and S. Piantadosi Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States Clin Cancer Res 16 2010 2443 2449
42. Avastin. Prescribing information. Genentech USA, Inc. South San Francisco, CA.
43. O.L. Chinot, T. de La Motte Rouge, and N. Moore AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme Adv Ther 28 2011 334 340
44. Clinicaltrials.gov Temozolomide and radiation therapy with or without bevacizumab in treating patients with newly diagnosed glioblastoma http://clinicaltrials.gov/ct2/show/NCT00884741 Accessed August 2, 2011
45. Clinicaltrials.gov Cilengitide, temozolomide, and radiation therapy in treating patients with newly diagnosed glioblastoma and methylated gene promoter status http://clinicaltrials.gov/ct2/show/NCT00689221 Accessed July 19, 2011
46. C.E. Pelloski, K.V. Ballman, and A.F. Furth Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma J Clin Oncol 25 2007 2288 2294 (Pubitemid 46954657)
47. R.K. Lai, L.D. Recht, and D.A. Reardon Final analysis of PFR in ACT III: A phase II trial of rindopepimut (CDX-110) with temozolomide in patients with newly diagnosed GBM [poster] 2010 Society for NeuroOncol 15th Annual Scientific Meeting November 1821, Montreal, Quebec, Canada 2010
48. J.H. Sampson, A.B. Heimberger, and G.E. Archer Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma J Clin Oncol 28 2010 4722 4729
49. L.M. Liau, R.M. Prins, and S.M. Kiertscher Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment Clin Cancer Res 11 2005 5515 5525 (Pubitemid 41060828)
50. D.E. Gerber, S.A. Grossman, and M. Zeltzman The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas Neurooncol 9 2007 47 52 (Pubitemid 46543488)
51. T.S. Armstrong, Y. Cao, and M.E. Scheurer Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors Neurooncol 11 2009 825 832
52. National Institute of Neurological Disorders and Stroke Brain and spinal tumors: hope through research www.ninds.nih.gov/disorders/brainandspinaltumors/ detail-brainandspinaltumors.htm#182883060 Accessed August 16, 2011
53. M.J. Glantz, B.F. Cole, and P.A. Forsyth Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 54 2000 1886 1893 (Pubitemid 30327107)
54. I.W. Tremont-Lukats, B.O. Ratilal, T. Armstrong, and M.R. Gilbert Antiepileptic drugs for preventing seizures in people with brain tumors Cochrane Database Syst Rev 2 2008 CD004424
55. S. Oberndorfer, M. Piribauer, and C. Marosi P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy J Neurooncol 72 2005 255 260 (Pubitemid 40867409)
56. A.A. Brandes, E. Scelzi, and G. Salmistraro Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study Eur J Cancer 33 1997 1592 1596 (Pubitemid 28123480)
57. E.O. Jenkins, D. Schiff, and N. Mackman Venous thromboembolism in malignant gliomas J Thromb Haemost 8 2010 221 227
58. T.J. Semrad, R. O'Donnell, and T. Wun Epidemiology of venous thromboembolism in 9489 patients with malignant glioma J Neurosurg 106 2007 601 608 (Pubitemid 46536455)
59. J.R. Perry, J.A. Julian, and N.J. Laperriere PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma J Thromb Haemost 8 2010 1959 1965